GREENWICH LIFESCIENCES, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $17.2M | $15.5M | $7.7M | $6.5M | $3.6M | $1.1M | $2.6M |
| SG&A Expense | — | $2.2M | $2.2M | $1.6M | $1.6M | $1.0M | $806.2K | $818.9K |
| Operating Income | — | $-19.4M | $-17.6M | $-9.3M | $-8.0M | $-4.6M | $-1.9M | $-3.4M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | — | $-19.4M | $-17.4M | $-8.9M | $-7.8M | $-4.6M | $-1.9M | $-3.4M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-1.43 | $-1.34 | $-0.69 | $-0.61 | $-0.35 | $-0.20 | $-1.52 |
| EPS (Diluted) | — | $-1.43 | $-1.34 | $-0.69 | $-0.61 | $-0.35 | $-0.20 | $-1.52 |
| Shares Outstanding (Basic) | 14.7M | 13.5M | 13.0M | 12.8M | — | 13.1M | 12.7M | 8.5M |
| Shares Outstanding (Diluted) | 14.7M | 13.5M | 13.0M | 12.8M | 12.9M | 13.1M | 12.7M | 8.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |